{"analyses":[{"ciLowerLimit":"0.461","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.760","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.591","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.4","upperLimit":"21.6","value":"19.4"},{"groupId":"OG001","lowerLimit":"11.0","upperLimit":"13.5","value":"12.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of randomization to the date of radiographically documented progressive disease (PD) based on investigator assessment, or the date of death due to any cause, whichever is first assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Part B: Ramucirumab+ Erlotinib"},{"description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Part B: Placebo+ Erlotinib"}],"paramType":"MEDIAN","populationDescription":"Part B: All randomized participants grouped according to their assigned treatment at randomization. Censored participants were: Part B: Ramucirumab+ Erlotinib= 102 and Part B: Placebo+ Erlotinib= 67. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","timeFrame":"Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)","title":"Part B: Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}